somatostatin analogue
Lanreotide dose
Answer
FDA label for LANREOTIDE ACETATE: The recommended starting dosage of Lanreotide Injection is 90 mg given via the deep subcutaneous route, at 4-week intervals for 3 months. Half-life on the label: 23 to 30 days. Trials with posted results tested 1 dose, most often 120 mg.
Not dosing advice.
FDA LABEL
What the approved labels state
LANREOTIDE ACETATE ANDA217193 · label of 2025-02-01 Regulator
The recommended starting dosage of Lanreotide Injection is 90 mg given via the deep subcutaneous route, at 4-week intervals for 3 months.
Half-life: 23 to 30 days (section 12.3).
SOMATULINE DEPOT NDA022074 · label of 2024-10-11 Regulator
The recommended starting dosage of SOMATULINE DEPOT is 90 mg given via the deep subcutaneous route, at 4-week intervals for 3 months.
Half-life: 23 to 30 days (section 12.3).
IN TRIALS
Doses tested in 34 trials with posted results
| Dose in the arm title | Trials | People on it | Phases |
|---|---|---|---|
| 120 mg | 6 | 533 | 2/3/4 |
Trial register Read from the titles of arms that received Lanreotide (n ≥ 20). An arm naming several doses counts under each; a schedule or escalation is on the trial record. All trials.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.